EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatitis B Virus Diagnosis Using Dried Blood Spots in the D.R. Congo: Overcoming Misdiagnosis to Achieve 2030 WHO Targets

Paula Martínez de Aguirre, Silvia Carlos, Samclide Mbikayi, Eduardo Burgueño, David Barquín, Céline Tendobi, Luis Chiva iD, África Holguín iD, Gabriel Reina iD

Medical Sciences · 26.05.2026 · 14 (2) · 271

DOI: 10.3390/medsci14020271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 26.05.2026. Verfasst von Paula Martínez de Aguirre und 8 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology Department, Clínica Universidad de Navarra, 31008 Pamplona, Spain. Hauptthemen laut MEDLINE: Hepatitis B, Hepatitis B virus, Dried Blood Spot Testing. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Gobierno de Navarra, Fundación Amigos de Monkole.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Hepatitis B remains a major public health concern in the Democratic Republic of the Congo (DRC). This study investigated HBV seroprevalence in Kinshasa and evaluated the diagnostic performance of rapid diagnostic tests (RDTs) compared with dried blood spot (DBS)–based immunoassays.

Methods

DBS samples collected between 2016 and 2022 were transported to Spain for HBsAg and HBc-Ab testing using two chemiluminescence platforms (ECLIA-COBAS (Roche) and ELFA-miniVIDAS (bioMerieux)). A subset of participants also underwent on-site HBsAg screening using Determine™ (Abbott) RDTs.

Results

Overall, active HBV infection was detected in 4.3% of participants and resolved infection in 14.3%, with no significant differences by age, sex, cohort, or HIV/HCV status. The RDT showed poor sensitivity (60% (95% CI: 26–88)) but high specificity (100% (95% CI: 98–100)), resulting in a 40% misdiagnosis rate. In contrast, DBS-based HBsAg immunoassays demonstrated excellent diagnostic accuracy, with both platforms achieving 100% sensitivity (ECLIA-COBAS 100%, 95% CI: 66–100; ELFA-miniVIDAS 100%, 95% CI: 99–100) and specificity (ECLIA-COBAS 100%, 95% CI: 98–100; ELFA-miniVIDAS 100%, 95% CI: 99–100). HBc-Ab detection showed platform-dependent variability, with lower sensitivity on ELFA-miniVIDAS (66% (95% CI: 46–82)) compared with ECLIA-COBAS (100% (95% CI: 96–100)). Predictive values were high across all assays, and inter-method agreement for HBsAg between RDT and chemiluminescence was good (Cohen’s kappa 0.71, p < 0.001).

Conclusions

These findings indicate moderate HBV transmission in Kinshasa and highlight the limited reliability of RDT-based screening. DBS proved to be a practical, robust, and scalable sampling method with outstanding diagnostic performance, making it well-suited for HBV testing in low-resource settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis BHepatitis B virusDried Blood Spot TestingHumansFemaleDemocratic Republic of the CongoMaleAdultRapid Diagnostic TestsHepatitis B Surface AntigensMiddle AgedDiagnostic ErrorsSensitivity and SpecificityImmunoassayYoung AdultSeroepidemiologic StudiesAdolescent

Stichwörter der Autor:innen

Hepatitis Bdried blood spot (DBS)misdiagnosisrapid diagnostic test (RDT)seroprevalencesub-Saharan Africa

Substanzen

Hepatitis B Surface Antigens

Autor:innen und Institutionen

  • Microbiology Department, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
  • Department of Preventive Medicine and Public Health, Universidad de Navarra, 31008 Pamplona, Spain.
  • IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Centre Hospitalier Monkole, H7FP+W6P, 10, Monkole Avenue, Kinshasa 4484, Democratic Republic of the Congo.
  • Department of Gynecology and Obstetrics, Clínica Universidad de Navarra, 28027 Madrid, Spain.
  • Laboratorio Epidemiología Molecular VIH-1, Hospital Ramón y Cajal-IRYCIS y CIBERESP, Madrid. Ctra. Colmenar Viejo, 28034 Madrid, Spain.

ORCID-Profile: Luis Chiva, África Holguín, Gabriel Reina

Förderung

  • Instituto de Salud Carlos III
  • Gobierno de Navarra
  • Fundación Amigos de Monkole
  • Government of Spain
  • Fondo de Investigación en Salud-FIS
  • Government of Navarre

Zitieren

APA

Martínez de Aguirre, P., Carlos, S., Mbikayi, S., Burgueño, E., Barquín, D., Tendobi, C., Chiva, L., Holguín, Á., & Reina, G. (2026). Hepatitis B Virus Diagnosis Using Dried Blood Spots in the D.R. Congo: Overcoming Misdiagnosis to Achieve 2030 WHO Targets. Medical Sciences, 14(2), 271. https://doi.org/10.3390/medsci14020271

Vancouver

Martínez de Aguirre P, Carlos S, Mbikayi S, Burgueño E, Barquín D, Tendobi C, et al. Hepatitis B Virus Diagnosis Using Dried Blood Spots in the D.R. Congo: Overcoming Misdiagnosis to Achieve 2030 WHO Targets. Medical Sciences. 2026;14(2):271. doi:10.3390/medsci14020271

BibTeX
@article{MartnezdeAguirre2026,
  author = {Martínez de Aguirre, Paula and Carlos, Silvia and Mbikayi, Samclide and Burgueño, Eduardo and Barquín, David and Tendobi, Céline and Chiva, Luis and Holguín, África and Reina, Gabriel},
  title = {Hepatitis B Virus Diagnosis Using Dried Blood Spots in the D.R. Congo: Overcoming Misdiagnosis to Achieve 2030 WHO Targets},
  journal = {Medical Sciences},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {271},
  doi = {10.3390/medsci14020271}
}
Kostenlos starten →